Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation reports developments in medical research programs focused on traumatic brain injury, PTSD, suicide ideation, dialysis-borne neuropathy and pruritus. The company’s updates describe its proprietary nasal spray approach for post-head-trauma treatment, its LDX compound, and work with Athena GTX, Athena Telemedicine Partners and scientists at Mississippi State University.
Recurring news also covers Halberd’s NeuroSense AI acquisition and behavioral intelligence platform, which combines multi-modal behavioral data with artificial intelligence for TBI research and clinical assessment. Other company updates address patent-related assets, government-contract efforts, private funding discussions, and OTC public-company communications.
Halberd Corporation (OTC PINK: HALB) provides an overview of its achievements and goals for 2022. The company focuses on biomedical R&D, targeting neurodegenerative diseases, with a proprietary treatment methodology. Key milestones include successful eradication of top antigens linked to diseases, the addition of patents, and plans for joint ventures and government grants. Forward goals encompass completing independent audits, filing a FORM-10, and expanding outreach and product lines. Halberd aims to enhance its technical capabilities and brand recognition to assure success for shareholders.
Halberd, Inc. (HALB) has achieved significant progress in its latest laboratory tests, successfully eliminating Beta Amyloid and Interleukin-4 from synthetic cerebrospinal fluid (CSF). This accomplishment aligns with HALB's objective to manage key antigens associated with neurodegenerative diseases such as Alzheimer's, PTSD, and ALS. The company has completed eradication tests for multiple target antigens and boasts three issued patents related to this technology. CEO William A. Hartman emphasized the uniqueness of HALB's approach compared to competitors, which reportedly eliminate only a fraction of Beta Amyloid.
Halberd Corporation (OTC PINK:HALB) is now registered with the Federal Government's System for Award Management, enabling it to bid on Federal contracts in biotechnology research and health supplements. This opens opportunities to serve military members and government agencies addressing neurodegenerative diseases like PTSD, Alzheimer's, and more. The company claims proof-of-concept for removing disease-related antigens from cerebral spinal fluid and plans to advance to in-vivo studies. Halberd has secured three patents and filed numerous applications to boost its market presence.
Halberd Corporation (OTC Pink: HALB) has successfully eliminated Interleukin-2 (IL-2) from synthetic cerebral spinal fluid (CSF) in preliminary tests. IL-2, a pro-inflammatory cytokine, is linked to neurodegeneration and neuroprotection in conditions like Alzheimer's Disease. Dr. Mitchell S. Felder emphasized this ability could halt Alzheimer's progression when combined with controls on other inflammatory cytokines. CEO William A. Hartman stated that this technology could revolutionize treatment for various neurodegenerative diseases and may lead to breakthroughs for related diseases like cancer.
Halberd Corporation (OTC PINK:HALB) announced a breakthrough in its ongoing research, achieving 100% eradication of Interleukin-12 (IL-12) from synthetic cerebral spinal fluid. This pro-inflammatory cytokine has been linked with Alzheimer's Disease, affecting over 6 million people in the U.S. and 40 million worldwide. CEO William A. Hartman mentions this technology aims to eliminate antigens related to neurodegenerative diseases, positioning Halberd as a unique player in this field. The company's future plans include promoting this technology to target conditions like Traumatic Brain Injury and PTSD.
Halberd Corporation (OTC PINK:HALB) announced a breakthrough achievement in neuroscience by successfully eradicating Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) during preliminary testing. This advancement is critical, as IL-1 is linked to various severe diseases including Alzheimer's and Multiple Sclerosis. The company's patented technology has previously eliminated other inflammatory cytokines, enhancing prospects for treating neurodegenerative conditions. Halberd aims to revolutionize treatments for diseases such as Alzheimer’s and Parkinson’s through ongoing research and patent protections.
Halberd Corporation (OTC PINK:HALB) has announced successful verification tests demonstrating a 100% elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF). This breakthrough, achieved through their patented process and laser irradiation, indicates potential new treatments for conditions like Alzheimer's Disease and PTSD. The company also highlighted previous success in eliminating Phosphorylated Tau and Interleukin 6, emphasizing ongoing research to address other inflammatory markers associated with neurodegenerative diseases.
Halberd Corporation (OTC PINK:HALB) announced a significant breakthrough in treating Alzheimer's Disease by eradicating 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) using its patented process and laser technology. This inflammatory cytokine is linked to the progression of Alzheimer's and obesity. The company aims to continue its research on eliminating other markers associated with neurodegenerative diseases. Halberd holds exclusive worldwide rights to multiple patents, enhancing its potential value for shareholders.
Halberd Corporation (OTC PINK:HALB) has filed a non-provisional patent application for a novel extracorporeal treatment targeting Covid-19 via radio frequency waves. This follows a provisional application and aims to enhance Halberd's intellectual property rights. The treatment uses a proprietary SARS-CoV-2 antibody attached to gold-coated iron nanoparticles, which, when exposed to radio frequency, neutralizes the virus. Halberd's Chairman emphasizes that while the focus remains on neurological diseases, this patent could increase scientific value.
Halberd Corporation (OTC PINK:HALB) has achieved a significant milestone by eliminating 100% of IL-6 from synthetic cerebrospinal fluid (CSF) during preliminary testing. Utilizing its patented extracorporeal and patent-pending laser eradication processes, IL-6 was eradicated in as little as three minutes. Elevated IL-6 levels are linked to neurological disorders, including PTSD, Chronic Traumatic Encephalopathy, and Alzheimer's Disease. The company plans to continue research towards eliminating other inflammatory cytokines and pursuing military endorsement for its advancements.